US 12,403,105 B2
Diagnosis and treatment of vitiligo
Jillian M. Richmond, Dayville, CT (US); John E. Harris, Sterling, MA (US); and James Pennock Strassner, Worcester, MA (US)
Assigned to University of Massachusetts, Westborough, MA (US)
Filed by University of Massachusetts, Boston, MA (US)
Filed on Aug. 15, 2024, as Appl. No. 18/805,702.
Application 17/667,699 is a division of application No. 16/608,116, granted, now 11,278,505, issued on Mar. 22, 2022, previously published as PCT/US2018/029185, filed on Apr. 24, 2018.
Application 18/805,702 is a continuation of application No. 18/607,636, filed on Mar. 18, 2024.
Application 18/607,636 is a continuation of application No. 18/234,923, filed on Aug. 17, 2023, abandoned.
Application 18/234,923 is a continuation of application No. 17/667,699, filed on Feb. 9, 2022, abandoned.
Claims priority of provisional application 62/489,191, filed on Apr. 24, 2017.
Prior Publication US 2024/0398730 A1, Dec. 5, 2024
Int. Cl. A61K 31/137 (2006.01); A61K 45/06 (2006.01); A61P 17/00 (2006.01); A61P 37/06 (2006.01)
CPC A61K 31/137 (2013.01) [A61P 17/00 (2018.01); A61K 45/06 (2013.01); A61P 37/06 (2018.01)] 9 Claims
 
1. A method of treating vitiligo in a subject, the method comprising:
identifying a subject having vitiligo; and
administering to the subject an anti-CD122 antibody at a dose and for a duration sufficient to reverse at least portion of the vitiligo, wherein the antibody is a humanized antibody comprising a heavy chain variable region (VH) comprising a VHCDR1, VHCDR2, and VHCDR3 from antibody ChMBC7 and a light chain variable region (VL) comprising a VLCDR1, VLCDR2, and VLCDR3 from antibody ChMBC7, or the antibody is HuABC2 or HUABC101.